Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015

Recommend to a Colleague print

 

REVIEWER: Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa, Canada

Efficacy
NNT analysis
Safety
Natalizumab discontinuation studies
NeuroSens Survey on first-line orals

Subscribe to read more

It takes 30 seconds
or login using your email address

Please enter the email address that you registered the newsletter with
Continue

Recommend to a Colleague

Related Posts

• Putting biomarkers into practice
  March 8, 2023
• CNS effects of Wegovy (semaglutide)
  February 28, 2023
• CLINICAL CASES IN MS – A YOUNG WOMAN WITH BREAKTHROUGH DISEASE ON FINGOLIMOD
  February 22, 2023
• Putting shared decision-making into practice
  February 16, 2023
• CLINICAL CASES IN MS – AN OLDER PATIENT WITH STABLE DISEASE
  February 9, 2023

Go back to home page